Pathophysiology and mechanisms of severe retinopathy of prematurity

Ophthalmology

Volumn 122, Issue 1, 2015, Pages 200-210

  Hartnett, M Elizabeth ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; BRAIN DERIVED NEUROTROPHIC FACTOR; ERYTHROPOIETIN; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OMEGA 3 FATTY ACID; OXYGEN; PLASMIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SEMAPHORIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; XANTHOPHYLL;

ANGIOGENESIS; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; BEAGLE; BIOLOGICAL ACTIVITY; BLINDNESS; CANINE MODEL; CAPILLARY DENSITY; CHILDHOOD DISEASE; DISEASE SEVERITY; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; HYPOXIA; INFANT NUTRITION; INFLAMMATION; MOUSE MODEL; NEUROPROTECTION; NONHUMAN; NUTRITIONAL STATUS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POSTNATAL GROWTH; PREMATURITY; PRIORITY JOURNAL; RAT MODEL; RETINA BLOOD VESSEL; RETINA DEVELOPMENT; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; REVIEW; SIGNAL TRANSDUCTION; TARGET CELL; ANIMAL; CLASSIFICATION; DISEASE MODEL; NEWBORN;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; INFANT, NEWBORN; RETINOPATHY OF PREMATURITY;

EID: 84920782368     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.07.050     Document Type: Review

References (51)

1. Terry TL. Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens: (1) preliminary report. Am J Ophthalmol 1942;25:203-4.
2. Schepens CL. A new ophthalmoscope demonstration. Trans Am Acad Ophthalmol Otolaryngol 1947;51:298-301.
3. Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med 2012;367:2515-26.
4. Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 2008;84:77-82.
5. Shah PK, Narendran V, Kalpana N. Aggressive posterior retinopathy of prematurity in large preterm babies in South India. Arch Dis Child Fetal Neonatal Ed 2012;97:F371-5.
6. Bizzarro MJ, Hussain N, Jonsson B, et al. Genetic susceptibility to retinopathy of prematurity. Pediatrics 2006;118:1858-63.
7. International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 2005;123:991-9.
8. Hartnett ME. Studies on the pathogenesis of avascular retina and neovascularization into the vitreous in peripheral severe retinopathy of prematurity (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2010;108:96-119.
9. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity randomized trial. Arch Ophthalmol 2003;121:1684-94.
10. Chan-Ling T, McLeod DS, Hughes S, et al. Astrocyte-endothelial cell relationships during human retinal vascular development. Invest Ophthalmol Vis Sci 2004;45:2020-32.
11. McLeod DS, Hasegawa T, Prow T, et al. The initial fetal human retinal vasculature develops by vasculogenesis. Dev Dyn 2006;235:3336-47.
12. Chan-Ling T, Gock B, Stone J. The effect of oxygen on vasoformative cell division: evidence that "physiological hypoxia" is the stimulus for normal retinal vasculogenesis. Invest Ophthalmol Vis Sci 1995;36:1201-14.
13. Bai Y, Ma JX, Guo J, et al. Müller cell-derived VEGF is a significant contributor to retinal neovascularization. J Pathol 2009;219:446-54.
14. Jiang Y, Wang H, Culp D, et al. Targeting Muller cellederived VEGF164 to reduce intravitreal neovascularization in the rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2014;55:824-31.
15. Rivera JC, Sapieha P, Joyal JS, et al. Understanding retinopathy of prematurity: update on pathogenesis. Neonatology 2011;100:343-53.
16. Gerhardt H, Golding M, Fruttiger M, et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003;161:1163-77.
17. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994;35:101-11.
18. Penn JS, Henry MM, Tolman BL. Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat. Pediatr Res 1994;36:724-31.
19. Cunningham S, Fleck BW, Elton RA, Mclntosh N. Transcutaneous oxygen levels in retinopathy of prematurity. Lancet 1995;346:1464-5.
20. Di Fiore JM, Kaffashi F, Loparo K, et al. The relationship between patterns of intermittent hypoxia and retinopathy of prematurity in preterm infants. Pediatr Res 2012;72:606-12.
21. Wang H, Smith GW, Yang Z, et al. Short hairpin RNA-mediated knockdown of VEGFA in Muller cells reduces intravitreal neovascularization in a rat model of retinopathy of prematurity. Am J Pathol 2013;183:964-74.
22. Wang H, Yang Z, Jiang Y, et al. Quantitative analyses of retinal vascular area and density after different methods to reduce VEGF in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2014;55:737-44.
23. Lutty GA, McLeod DS, Bhutto I, Wiegand SJ. Effect of VEGF Trap on normal retinal vascular development and oxygen-induced retinopathy in the dog. Invest Ophthalmol Vis Sci 2011;52:4039-47.
24. Saito Y, Geisen P, Uppal A, Hartnett ME. Inhibition of NAD(P)H oxidase reduces apoptosis and avascular retina in an animal model of retinopathy of prematurity. Mol Vis [serial online] 2007;13:840-53. Available at: http://www.molvis.org/molvis/v13/a92/. Accessed August 2, 2014.
25. Niesman MR, Johnson KA, Penn JS. Therapeutic effect of liposomal superoxide dismutase in an animal model of retinopathy of prematurity. Neurochem Res 1997;22:597-605.
26. Schaffer DB, Palmer EA, Plotsky DF, et al. Prognostic factors in the natural course of retinopathy of prematurity. Ophthalmology 1993;100:230-7.
27. Sears JE, Hoppe G, Ebrahem Q, Anand-Apte B. Prolyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy. Proc Natl Acad Sci U S A 2008;105:19898-903.
28. Wang H, Zhang SX, Hartnett ME. Signaling pathways triggered by oxidative stress that mediate features of severe retinopathy of prematurity. JAMA Ophthalmol 2013;131:80-5.
29. Wang H, Yang Z, Jiang Y, Hartnett ME. Endothelial NADPH oxidase 4 mediates vascular endothelial growth factor receptor 2-induced intravitreal neovascularization in a rat model of retinopathy of prematurity. Mol Vis [serial online] 2014;20:231-41. Available at: http://www.molvis.org/molvis/v20/231/. Accessed August 2, 2014.
30. Wang H, Byfield G, Jiang Y, et al. VEGF-mediated STAT3 activation inhibits retinal vascularization by down-regulating local erythropoietin expression. Am J Pathol 2012;180:1243-53.
31. Byfield G, Budd S, Hartnett ME. The role of supplemental oxygen and JAK/STAT signaling in intravitreous neovascularization in a ROP rat model. Invest Ophthalmol Vis Sci 2009;50:3360-5.
32. Holmes JM, Duffner LA. The effect of postnatal growth retardation on abnormal neovascularization in the oxygen exposed neonatal rat. Curr Eye Res 1996;15:403-9.
33. Hellström A, Smith LE, Dammann O. Retinopathy of prematurity. Lancet 2013;382:1445-57.
34. Hartnett ME, Morrison MA, Smith S, et al. Genetic variants associated with severe retinopathy of prematurity in extremely low birth weight infants. Invest Ophthalmol Vis Sci 2014 Aug 12. pii: IOVS-14-14841. doi: 10.1167/iovs.14-14841.
35. McColm JR, Geisen P, Hartnett ME. VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP. Mol Vis [serial online] 2004;10:512-20. Available at: http://www.molvis.org/molvis/v10/a63/. AccessedAugust 2, 2014.
36. Budd S, Byfield G, Martiniuk D, et al. Reduction in endothelial tip cell filopodia corresponds to reduced intravitreous but not intraretinal vascularization in a model of ROP. Exp Eye Res 2009;89:718-27.
37. Zeng G, Taylor SM, McColm JR, et al. Orientation of endothelial cell division is regulated by VEGF signaling during blood vessel formation. Blood 2007;109:1345-52.
38. Hartnett ME, Martiniuk D, Byfield G, et al. Neutralizing VEGF decreases tortuosity and alters endothelial cell division orientation in arterioles and veins in a rat model of ROP: relevance to plus disease. Invest Ophthalmol Vis Sci 2008;49:3107-14.
39. Mintz-Hittner HA, Kennedy KA, Chuang AZ. BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011;364:603-15.
40. Patel RD, Blair MP, Shapiro MJ, Lichtenstein SJ. Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity [letter]. Arch Ophthalmol 2012;130:801-2.
41. McCloskey M, Wang H, Jiang Y, et al. Anti-VEGF antibody leads to later atypical intravitreous neovascularization and activation of angiogenic pathways in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2013;54:2020-6.
42. Greenberg KP, Geller SF, Schaffer DV, Flannery JG. Targeted transgene expression in Muller glia of normal and diseased retinas using lentiviral vectors. Invest Ophthalmol Vis Sci 2007;48:1844-52.
43. Tokunaga CC, Mitton KP, Dailey W, et al. Effects of anti-VEGF treatment on the recovery of the developing retina following oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 2014;55:1884-92.
44. American Academy of Pediatrics Section on Ophthalmology, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2013;131:189-95.
45. Chen J, Connor KM, Aderman CM, et al. Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest Ophthalmol Vis Sci 2009;50:1329-35.
46. Ohls RK, Christensen RD, Kamath-Rayne BD, et al. A randomized, masked, placebo-controlled study of darbepoetin alfa in preterm infants [report online]. Pediatrics 2013;132:e119-27.
47. Yang Z, Wang H, Jiang Y, Hartnett ME. VEGFA activates erythropoietin receptor and enhances VEGFR2-mediated pathological angiogenesis. Am J Pathol 2014;184:1230-9.
48. Wu C, Vanderveen DK, Hellstrom A, et al. Longitudinal postnatal weight measurements for the prediction of retinopathy of prematurity. Arch Ophthalmol 2010;128:443-7.
49. Capozzi ME, McCollum GW, Penn JS. The role of cytochrome p450 epoxygenases in retinal angiogenesis. Invest Ophthalmol Vis Sci 2014;55:4253-60.
50. Penn JS, Rajaratnam VS. Inhibition of retinal neovascularization by intravitreal injection of human rPAI-1 in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2003;44:5423-9.
51. Chen J, Hellstrom A, Smith LE. Author response: different efficacy of propranolol in mice with oxygen-induced retinopathy: could differential effects of propranolol be related to differences in mouse strains [letter]? Invest Ophthalmol Vis Sci 2012;53:7728-9.